Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Earnings per Share (Diluted) : $-0.75 (TTM As of Sep. 2018)

Keryx Biopharmaceuticals Earnings per Share (Diluted) Chart

Keryx Biopharmaceuticals Annual Data
	Trend	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17
Earnings per Share (Diluted)		Get a 7-Day Free Trial					-0.58	-1.23	-1.19	-1.52	-1.43

Keryx Biopharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Earnings per Share (Diluted)	Get a 7-Day Free Trial															-0.20	-0.25	-0.18	-0.18	-0.14

Competitive Comparison of Keryx Biopharmaceuticals's Earnings per Share (Diluted)

For the Biotechnology subindustry, Keryx Biopharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Keryx Biopharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keryx Biopharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Keryx Biopharmaceuticals's PE Ratio falls into.

Keryx Biopharmaceuticals Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Keryx Biopharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2017 is calculated as

Keryx Biopharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2018 is calculated as

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Keryx Biopharmaceuticals  (NAS:KERX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Keryx Biopharmaceuticals Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Keryx Biopharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Business Description